Eli Lilly announced the acquisition of three vaccine biotechs — Curevo, LimmaTech, and Vaccine Co. — for close to $4 billion combined. The portfolio spans a Phase 2 shingles vaccine, a Phase 1 Staphylococcus aureus program, and a preclinical Epstein-Barr Virus candidate. None of the three assets carries a reimbursement decision in any major market.
The commercial value of this deal depends entirely on access outcomes that no HTA body has yet evaluated. Access Impact Vaccine reimbursement differs structurally from small-molecule or biologic drug access. In the United States, coverage decisions for vaccines are shaped in part by ACIP recommendations, which weigh clinical evidence, cost-effectiveness, and population-level budget impact. In EU member states, national HTA bodies apply criteria that vary materially in stringency.
In the UK, JCVI recommendations interact with NICE appraisals. Clearing the clinical bar — as Curevo’s Phase 2 data suggest — is not the same as clearing the reimbursement bar. For Curevo’s shingles vaccine, the access profile is shaped primarily by Comparator Appropriateness. GSK’s Shingrix is the dominant incumbent across major markets, supported by robust real-world evidence and established cost-effectiveness modeling. A new entrant with ‘similar efficacy and fewer side effects’ does not automatically translate into a superior access position. Payers and HTA bodies will ask whether the tolerability improvement generates measurable health utility gains or reduces downstream costs at the population level. If the answer is equivocal, the cost-effectiveness case weakens regardless of the clinical profile. For LimmaTech’s S. aureus vaccine, the horizon is longer. Bacterial vaccines face particular challenges in demonstrating cost-effectiveness at scale, especially in markets where existing infection control measures define the comparator. For Vaccine Co.’s EBV program, reimbursement implications are speculative; the asset is preclinical.
Comparator Appropriateness
Curevo enters a market in which Shingrix has established both the clinical and economic standard. Any new entrant is evaluated against it — not against older vaccines or placebo. ‘Fewer side effects’ is a meaningful clinical differentiator, but its access value depends on whether it translates to demonstrable improvements in health-related quality of life or cost savings at population scale. That evidence does not yet exist. Without it, comparative benefit assessments in markets such as Germany (IQWiG) or France (HAS) will be challenging.
Cost-Effectiveness
Vaccine cost-effectiveness relies on modeled assumptions about disease incidence, prevention of downstream complications, and the cost of alternatives. For shingles, that modeling framework is well-developed — which means the bar for a new entrant is clearly defined, and any submission must match or exceed it. Curevo will need to compete within an existing cost-effectiveness framework, not establish a new one. That is a structurally harder position than entering a market with no established comparator.
Evidence Quality and Robustness Two of the three acquired assets are early-stage (Phase 1 or preclinical). Acquisition valuations at this stage reflect projected efficacy and safety. Payers will eventually assess the same assets on demonstrated cost-effectiveness and comparative benefit. The gap between projected and demonstrated value is where market access risk accumulates — and where deal valuations have historically been tested against reality. Risk Signal Lilly paid close to $4 billion for three vaccine assets without a single
HTA evaluation or reimbursement decision among them. That is not unusual for acquisitions of this scale — but it means the commercial case rests entirely on projected access outcomes. The market access risk embedded in this portfolio is real, material, and, at this stage, unquantified. Investors and portfolio managers pricing this deal are implicitly forecasting reimbursement success for assets that have not been evaluated by NICE, IQWiG, HAS, or ICER. Clinical promise at Phase 2 is not a reimbursement position. The question is whether that distinction was priced in.
#MarketAccess #HTA #MARArating Explore other Lilly’s top Phase 3 candidates independent assessments:
https://mararating.com/report/retatrutide-for-obesity-±-metabolic-disorders-as-of-july-2025-market-access-risk-assessment/